BLOPEPBOLANG BIOTECHNOLOGY

Amylin receptor peptide agonist

Eloralintide

Eloralintide, also described as LY3841136, is investigated as an amylin receptor agonist in cellular, animal and early clinical studies.

SKU: EL5
BLOPEP vial — representative image
Representative image
Quantity per vial

Availability: To be confirmed

10-vial kit

10 × 5 mg = 50 mg / box

$399.00 / boxCalculated equivalent: $39.90 per vial. Sold by package.

Catalog price in USD.

Requested: 10 vials · 50 mg

Products subtotal$399.00

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Mixed · Study formulation · Receptor assays, animal experiments and phase 1 cohorts

Amylin receptor pharmacology

Eloralintide showed receptor-selectivity differences across species; the reported early clinical work does not establish long-term outcomes.

Briere et al., 2025 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

Eloralintide — amylin receptor peptide agonist. The literature identity must be matched to the documented chemical form and composition of the supplied material.

Assays compared AMY1, AMY3 and calcitonin receptors across species. Activation preference at human receptors was not identical to rat receptors. Translational research included animals and an early human study; receptor selectivity alone does not establish long-term clinical benefit.

  • AMY1R

Briere et al., 2025

Studied findings 1
Mixed · Study formulation

Amylin receptor pharmacology

Receptor assays, animal experiments and phase 1 cohorts

Eloralintide showed receptor-selectivity differences across species; the reported early clinical work does not establish long-term outcomes.

View context
Study design
Original-study abstract; experimental design described in linked source
Sample scope / arm
Not extracted; consult original study
Comparator
See original-study context
Experimental context (not instructions for use)
Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract
Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Briere et al., 2025

Sources and studies 2
  1. Eloralintide — PubChem molecular identity

  2. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

    Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, Long A, Allen D, O'Farrell L, Bowen B, Pratt E, Tidemann-Miller B, Tham LS, Ibriga H, Alsina-Fernandez J, Mather KJ, Haupt A, Bhattachar SN · 2025 · Molecular metabolism

    DOI: 10.1016/j.molmet.2025.102271

Specifications and packaging

Nominal variant content; analytical results belong to the documented batch.

Material type
Peptide
Molecular formula (literature identity)
C201H319N49O65S2
Molecular weight (literature identity)
4526 g/mol
SKU
EL5
Container or format
vial
Amount per unit
5 mg
Units per package
10
Nominal content per package
50 mg
Source commercial specification
5 mg

Quality and analyses

Review specifications, analytical results and documentation for published batches.

Purity
>99%
Type
Declared specification

Published batches

Batch results have not yet been published on this page.

Look up batch

Storage

Consult the specific conditions in the supplied material documentation.

Delivery and commercial terms

Freight, timing and import terms will be confirmed in the quote for the selected destination.

Other materials in this area

View category →